NCT06139666
The Effect of Liposomal Bupivacaine Nerve Block (Exparel) in Rotator Cuff Surgery
Enrolling by Invitation
PHASE4Ages 18+InterventionalTreatmentThe Cooper Health SystemInvestigator-initiated
~160 participants
Updated 2024-08-20 on ClinicalTrials.gov
What's tested:Exparel Injectable SolutionBupivacaine Injectable Solution
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Use of pain medications
Measured over 2 week postoperative visit
Conditions
Where it's being run
1 sites across 1 statesNew Jersey1
Study leadership
- Catherine J Fedorka, MD · PRINCIPAL_INVESTIGATOR · The Cooper Health System
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Patients above 18 years of age
Undergoing rotator cuff surgery or shoulder arthroscopy using an interscalene block
Exclusion
Patients with preexisting chronic obstructive pulmonary disease (COPD) or respiratory issues precluding the use of an interscalene block
Pregnant women, women nursing infants
Patients with preexisting liver disease
Patients unwilling to have interscalene block performed
Patients allergic to bupivacaine, liposomal bupivacaine, or any ingredients contained within the two drugs listed
What this trial measures
- Use of pain medications2 week postoperative visit
Patients will be asked to bring their bottle of pain medication prescribed after surgery to their first office visit so a narcotic pill count can be performed. Patients will record their pain pill consumption every day for 2 weeks in a study journal. The journal containing the pill count will be collected at the 2 week visit in the office. Opioid consumption will be quantified as milligram of opioid equivalents (MME).